Full text is available at the source.
Abstract
Baseline dietary quality and nutritional risk among treatment-eligible populations for obesity management remain poorly characterized.
- Glucagon-like peptide-1 receptor agonist anti-obesity medications (GLP-1 RA AOMs) are gaining popularity for managing obesity.
- There is limited understanding of the dietary habits of individuals eligible for these medications.
- Nutritional risks in these populations have not been thoroughly assessed.
Simplified